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Abstract: Type 2 diabetes is a major public health concern. Screening and early diagnosis 
  followed by prompt and aggressive treatment interventions can help control progression of 
diabetes and its complications. Nurses are often the first healthcare team members to interact 
with patients and are being called on to apply their specialized knowledge, training, and skills 
to educate and motivate patients with diabetes about insulin use and practical ways to achieve 
treatment goals. Clinical nurse specialists possess specific training and skills to provide this level 
of care, while staff or office-based nurses may be trained by physicians to fulfill a task-specific 
role. This manuscript reviews the benefits of intensive glycemic control in type 2 diabetes, 
therapeutic goals and guidelines, advances in insulin therapy, and contribution of nurses in over-
coming barriers to insulin initiation and related aspects of diabetes care. Nurses are particularly 
well positioned to fill the gap and improve efficiency in diabetes-related healthcare by assisting 
patients with insulin initiation and other aspects of glycemic self-management.
Keywords: insulin, diabetes, diabetes educator, hypoglycemia, diabetes counseling, insulin 
clinic, insulin pens
Introduction
Diabetes is a public health matter of grave concern associated with serious long-
term consequences and escalating healthcare costs, with an ever-rising incidence 
(∼90% between 1997 and 2007) and prevalence (from 4.8 to 9.1 per 1000 population in 
the US).1 With such alarming statistics, the role of nurses in helping patients to control 
type 2 diabetes-associated morbidity and mortality is becoming increasingly important. 
Nurses, on the front lines, can screen patients for early diabetes identification, recognize 
and initiate corrective measures for inadequate treatment regimens, help patients set 
and achieve therapeutic goals, and assess diabetes-related complications as they arise. 
In so doing, they can assume an active role in educating patients about the progressive 
nature of type 2 diabetes and the importance of early, intensive therapy.2
Based on a preponderance of evidence from a number of landmark studies 
  (summarized in Table 13–17 and illustrated in Figure 14), intensive treatment to achieve 
optimal glycemic control is associated with a lower incidence of cardiovascular and 
microvascular complications.18
Professional diabetes organizations, such as the American Diabetes Association 
(ADA), the American Association of Clinical Endocrinologists (AACE), and the 
European Association for the Study of Diabetes (EASD), have set aggressive goals 
in their guidelines for glycemic control (Table 2).14,15,17,19 Because an estimated 2 
out of 3 people fail to meet the AACE target hemoglobin A1C (HbA1C) goal of 6.5% Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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Figure  1  relationship  of  hemoglobin  A1c  (HbA1c)  and  incidence  of  diabetes 
complications.4 in the United Kingdom Prospective Diabetes study (UKPDs), each 
percentage point reduction in HbA1c was linked with substantial risk reductions in 
diabetes-related morbidity and mortality.
Table  1  selected  major  evidence  and  rationale  for  intensive 
diabetes management
Study
•   The UKPDs (United Kingdom Prospective Diabetes study) found 
that poor glycemic control in patients with type 2 diabetes is 
associated with an increased risk of cardiovascular complications, 
including coronary heart disease, myocardial infarction, and peripheral 
vascular disease, as well as microvascular complications and death.3 
Figure 1 shows the relationship of hemoglobin A1c (HbA1c) to    
diabetes-related complications.4
•  The DccT (Diabetes control and complications Trial) reported that 
maintaining fasting plasma glucose (FPG) between 70 and 120 mg/dL 
(3.89–6.67 mmol/L) and postprandial glucose (PPG) ,180 mg/dL 
(10 mmol/L) helps sustain endogenous insulin secretion.5 residual 
beta-cell function, in turn, is associated with better metabolic control 
and a lower risk of hypoglycemia and chronic complications, such as 
retinopathy and microalbuminuria.6
•   The eDic (epidemiology of Diabetes interventions and complications) 
study found that early glycemic control reduces the risk of 
cardiovascular events.7
•   The Aric (Atherosclerosis risk in communities) study reported that 
elevated HbA1c leads to atherosclerosis and cardiovascular disease.8,9
•   The steno-2 study found that intensive, multifactorial intervention 
reduced diabetes-related mortality and cardiovascular events.10
•   The ADvANce (Action in Diabetes and vascular Disease) study 
found that intensive glucose control reduced major macrovascular 
and microvascular events, primarily due to a 21% reduction in 
nephropathy.11
•   Li et al4,12 reported that short-term intensive insulin therapy titrated to 
maintain FPG ,110 mg/dL (6.11 mmol/L) and PPG ,160 mg/dL 
(8.89 mmol/L) prevented progression of beta-cell dysfunction and 
insulin resistance in newly diagnosed type 2 diabetic patients with 
severe hyperglycemia.
•   Weng et al3,13–17 found that hyperglycemia is brought under control 
more quickly, and the effects of insulin on beta-cell function are 
superior to those of oral hypoglycemic agents.
or less,20 diabetes management can benefit from a deeper, 
more direct involvement by nurses. The purpose of this 
manuscript is to review the benefits of intensive glycemic 
control in type 2 diabetes, therapeutic goals and guidelines, 
advances in insulin therapy, and contribution of nurses in 
overcoming barriers to insulin initiation and related aspects 
of diabetes care.
Early initiation of insulin to improve 
diabetes management
Beta-cell dysfunction and insulin resistance are the main 
physiological defects responsible for the development 
of hyperglycemia. Chronically elevated blood glucose 
further compromises beta-cell function, eventually lead-
ing to a complete shutdown of insulin production. In the 
early stages of type 2 diabetes, patients may be able to 
control hyperglycemia with oral antidiabetic drug (OAD) 
therapy. However, the progressive nature of type 2 
  diabetes will require that most patients eventually switch 
to   combination therapy that includes insulin or convert 
completely to insulin.21,22 Used in adequate doses, insulin 
is the most effective diabetes   medication, because it can 
decrease any elevated level of HbA1C to, or very close to, 
the therapeutic goal.14
Consensus guidelines from the ADA/EASD   advocate 
insulin as the second step after failure on metformin 
  monotherapy to achieve an HbA1C # 7%.14 This applies to 
patients who are symptomatic or have HbA1C . 8.5%. For 
patients without symptoms or with HbA1C levels that are   better 
  controlled, adding a sulfonylurea may be an   appropriate sec-
ond step. In treated patients whose HbA1C remains . 7.0%, 
insulin therapy should be initiated or the dose titrated upward. 
For patients with an initial HbA1C . 10%, insulin is recom-
mended as first-line therapy. Table 3   summarizes the main 
differences between oral therapies, some newer   therapies for 
diabetes management (ie, incretin-based   therapies), insulin 
Table 2 Therapeutic goals for FPG, PPG, and HbA1c
FPG 2-h PPG HbA1C
ADA19 90–130 mg/dL  
(5–7.22 mmol/L)
,180 mg/dL  
(10 mmol/L)
,7%
iDF17 ,110 mg/dL  
(6.11 mmol/L)
,145 mg/dL  
(8.06 mmol/L)
,6.5%
ADA/eAsD  
consensus14
70–130 mg/dL  
(3.89–7.22 mmol/L)
,180 mg/dL  
(10 mmol/L)
,7%
AAce15 ,100 mg/dL  
(5.56 mmol/L)
,140 mg/dL  
(7.78 mmol/L)
#6.5%
Abbreviations:  FPG,  fasting  plasma  glucose;  PPG,  postprandial  glucose;  HbA1c, 
hemoglobin A1c; ADA, American  Diabetes Association;  iDF,  international  Diabetes 
Federation, eAsD, european Association for the study of Diabetes; AAce, American 
Association of clinical endocrinologists.Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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Table 3 Differentiating available diabetes therapies14,15,23–28
Antidiabetic agent Advantages Disadvantages
Metformin Weight neutral, inexpensive, oral Gi side effects, rare lactic acidosis
Thiazolidinediones Improved lipid profile, oral Fluid retention, weight gain, cHF, 
may not see reduction in glucose for 
several weeks, expensive, increased 
cardiovascular risk
Alpha-glucosidase inhibitors Weight neutral, oral Frequent Gi side effects, 3 times/day 
dosing, expensive
sulfonylureas inexpensive, oral Weight gain, hypoglycemia
Glinides short duration Hypoglycemia, 3 times/day dosing, 
expensive
DPP-4 inhibitors 
 •  saxagliptin
 •  sitagliptin
Weight neutral, less hypoglycemia, oral Lack of long-term data regarding 
safety and efficacy
GLP-1 agonists
 •  exenatide
 •  Liraglutide
Less hypoglycemia, weight loss injections, lack of long-term data on 
safety and efficacy
insulin inexpensive, no dose limit,  
improved lipid profile
injections, monitoring, hypoglycemia, 
weight gain
Human insulin
 •  regular or short acting
 •  intermediate acting (NPH)
Many physicians still most comfortable 
with standard insulin therapy
Limited pharmacokinetic/
pharmacodynamic features, 
hypoglycemia, injections, monitoring, 
weight gain, variability in time-action 
profile
insulin analogs
 •  rapid-acting analogs
 ○  Aspart
 ○  Lispro
 ○  Glulisine
 •  Long-acting basal analogs
 ○  Glargine
 ○  Detemir
 •  Premixed analogs
 ○  Biphasic insulin aspart 70/30
 ○  insulin lispro 75/25
 ○  insulin lispro 50/50
Less hypoglycemia than human insulin,  
absorption more consistent, less weight  
gain; rapid- and long-acting formulations, 
predictable time–action profiles,  
simplified dosing with premixes
injections, monitoring
Devices for insulin delivery
 •  Traditional vial and syringe some physicians most comfortable with 
standard vial and syringe insulin therapy
can be complicated to administer, 
not discreet, time consuming, and 
potential for dosing errors; patients 
may have needle aversion
 •  Pen-injection devices convenient, discreet, simple, may improve  
confidence/adherence and reduce  
insulin-related adverse events, good  
for patients who have vision or dexterity 
problems, decreased dosing errors  
and more accurate dosing
some patients are averse to 
injections in any form
Abbreviations: Gi, gastrointestinal; cHF, congestive heart failure; DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide 1; NPH, neutral protamine Hagedorn.
formulations, and convenient injection devices for insulin 
delivery.14,15,23–28 Approaches to insulin initiation should 
be customized to the patients’ needs. Table 4 provides an 
overview of 3 common ways to initiate insulin.4,9,14,15,19, 29-40 
Specific dosing information depends on the method used, 
and the prescribing information should be consulted for the 
particular insulin products that are chosen and individualized 
for the patient.
Flexibility in diabetes care  
and quality of life: impact  
of insulin analogs and pens
Patients’ concerns about flexibility and lifestyle, such as 
misperceptions about timing of meals and the need to carry 
insulin vials, needles, and syringes, can be major barriers 
to insulin initiation. Nurses can intervene and help patients 
identify and transition to therapies that are flexible, simple, Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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convenient, and well suited to their patients’ lifestyles so 
adherence and quality of life are maximized.
Older human insulin formulations (eg, neutral protamine 
Hagedorn [NPH] and regular insulin) are characterized 
by unpredictable pharmacokinetic and pharmacodynamic 
time–action profiles that produce variable effects. When 
the   physiological or normal pattern of insulin response to 
food intake is not reproduced, hypoglycemia and weight 
gain can occur.41,42 These undesirable effects, in turn, result 
in a low degree of satisfaction and poor therapy adherence. 
Fortunately, the choices of insulin formulations and delivery 
systems have expanded considerably in the last decade.23,43 
Insulin analogs were specifically designed to mimic the 
body’s physiological insulin response (Figure 2).44
The long-acting insulin analogs (glargine and detemir) 
have important advantages over NPH. Due to their protracted 
duration of action, they can be administered as once-daily 
injections. The lack of a distinct peak in insulin activity 
and less variability in plasma insulin levels after injection 
are believed to account for the lower risk of hypoglycemia, 
particularly at night, when there is a long delay between 
meals.43,45 Despite having similar efficacy in terms of lower-
ing HbA1C and fasting plasma glucose (FPG), most studies 
show a 22% to 47% lower risk of nocturnal hypoglycemia and 
25% to 34% lower risk of severe hypoglycemia with insulin 
analogs compared with NPH.43,46,47 For patients whose con-
cern is additional weight gain when initiating insulin, detemir 
is a good choice; it has been shown to cause 1.4 to 1.6 kg less 
weight gain, on average, than NPH.48,49 In one study, patients 
with type 2 diabetes with a higher baseline body mass index 
(> 35kg/m2)  who received detemir lost an average of 0.5 kg 
compared with those receiving NPH, who gained an average 
of 2.4 kg, at equivalent levels of glycemic control.49 Patients 
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Figure 2 Approximate pharmacokinetic profiles of rapid- and long-acting insulin 
analogs as compared with an idealized profile of physiological insulin secretion.44
copyright © 2007 [Lippincott, Williams & Wilkins] reprinted with permission from 
Boyle  PJ,  Zrebiec  J.  Management  of  diabetes-related  hypoglycemia.  South  Med  J. 
2007;100(2):183–194.44
Table 4 insulin initiation strategies
The AAce notes that insulin can be initiated by addition to any and all 
oral antidiabetic drug (OAD) therapies, as long as appropriate blood 
glucose monitoring is performed. several different approaches are 
possible: 1) add a basal insulin,29,30 2) add a premixed insulin,31 or 3) add 
rapid-acting insulin boluses at mealtimes.9,32,33 The specific approach 
and insulin doses will depend on individual patients’ needs, preferences, 
HbA1c levels, and fasting plasma glucose (FPG) levels.
Initiation with basal insulin
•   Basal initiation therapy aims to normalize fasting blood glucose and 
HbA1c. Metformin is the preferred first-line OAD for patients with type 2 
diabetes but can be expected to reduce HbA1c values by only ∼1.5%.14,34,35
•   To achieve target HbA1c goals, basal insulin is added to metformin, 
typically at a dose of 10 units/day.
•   Adjustment of the daily dose will depend on the FPG and on the basal 
insulin selected.36,37
•   Two long-acting basal insulin analogs, insulin detemir and glargine, have 
pharmacodynamic profiles that provide up to 24-hour basal insulin 
levels, generally with a once-daily injection at bedtime.
•   Because type 2 diabetes is a progressive disease, most patients will 
ultimately require the addition of rapid-acting bolus insulin injections at 
mealtimes to control postprandial glucose (PPG) (see below).
•   A basal-bolus regimen is ideal for many patients, as it mimics the 
body’s constant release of insulin throughout the day and supplements 
the body’s need for insulin after a meal.
Premixed insulins
•   Premixed insulins are formulated to combine both basal and   rapid- 
acting components in 1 injection and thus provide a simple way to 
achieve near-normal insulin profiles at mealtime and between meals.
•   Premixed insulins are easy to use, ensure that the correct amount of 
insulin is injected every time, and may improve adherence to therapy. 
They are especially helpful for patients who are older, averse to 
multiple injections, or prefer a simple insulin regimen.
•   Premixed insulins are given in once-, twice-, or 3-times daily schedules, 
depending on the patient’s needs.
•   When initiating a premixed insulin, metformin should be continued, but if 
the patient is currently taking a secretagogue, it should be discontinued.
•   individuals who eat regular meals on a schedule are ideally suited for 
premixed insulins; however, premixes are not a preferred option for 
patients with varied daily schedules or those who require flexibility 
around mealtimes.
•   Specific dosing and titration information depend on the formulation 
chosen.
Rapid, short-acting insulin injections at mealtime
•   Tight control over PPG excursions can be exerted using mealtime 
bolus insulin injections.
•   As beta-cell function declines with disease progression, prandial insulin 
injections will eventually be required by most patients with type 2 
diabetes.
•   controlling PPG levels so they remain below 140 to 180 mg/dL  
(7.78–10 mmol/L)19 is important to delay the onset of vascular 
damage,4,39 and contributes to achievement of overall HbA1c goals.14,40
•   Adding a bolus injection of a rapid-acting mealtime insulin analog 
(lispro, aspart, or glulisine) is ideally suited for patients who require 
flexibility, since it may be given immediately before or even during a 
meal, ie, “inject and eat” rather than waiting 15 to 30 minutes with 
regular insulin. The dose can be varied based on the patient’s glucose 
levels or the size/type of meal. This approach is supported by AAce 
medical guidelines.15Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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with type 2 diabetes participating in a treat-to-target study 
with a basal-bolus insulin regimen gained significantly less 
weight (1.2 ± 4 kg) when treated with detemir compared with 
glargine (2.7 ± 4 kg; P = 0.001) after 26 weeks, despite achiev-
ing   similar reductions in HbA1C (1.1% vs 1.3%, respectively) 
and with similar hypoglycemia incidence.50 The lack of weight 
gain observed with long-  acting detemir compared with NPH 
and glargine makes it ideally suited for patients with type 2 
diabetes who tend to be overweight and for whom weight 
gain could   present additional health risks.
The rapid-acting insulin analogs (lispro, aspart, and 
glulisine) have improved time–action profiles that also offer 
several advantages over fast-acting regular insulin. These 
advantages include better efficacy in lowering postprandial 
glucose (PPG), increased safety due to a lower risk of late 
postprandial hypoglycemia, less blood glucose variability, 
and greater flexibility around mealtime dosing and timing 
of injections.43 Because the onset of action is between 5 and 
15 minutes compared with 30 to 60 minutes for regular 
insulin,23 the rapid-acting analogs can be injected immedi-
ately before, or even after, the meal has begun. This mealtime 
flexibility can have a positive impact on quality of life and 
promote satisfaction and adherence to therapy.51
Premixed insulin analogs, containing both a long-acting 
and a rapid-acting formulation, can offer even more simplicity 
and convenience for patients and provide excellent glycemic 
control, although sometimes at the expense of additional 
hypoglycemia and weight gain. Three premixed insulin 
analogs (biphasic insulin aspart 70/30, insulin lispro 75/25, 
and insulin lispro 50/50) are available in the US and come 
in easy-to-use pen devices.27 Patients in a study of premixed 
insulin achieved lower HbA1C levels than with once-daily basal 
insulin (7.1% vs 7.7%, respectively; P , 0.001) with a similar 
low occurrence of hypoglycemia events (0.8 vs 0.5 per person 
per month, respectively).52 A comprehensive review compar-
ing premixed insulins to basal insulin noted that twice-daily 
administration of a premixed insulin decreased HbA1C between 
1% and 2.7% compared with 0.4% to 2.4% with basal insulin 
analogs (P , 0.01), with slightly higher overall hypoglycemia 
and similar nocturnal or severe hypoglycemia.53
Use of a vial with a syringe can be difficult and cumber-
some, particularly for patients with diabetes-related visual 
disturbances, dexterity issues, or physical impairments. 
Today, the more patient-friendly insulin pens prefilled with 
insulin analogs are discreet and convenient and may help 
patients overcome social embarrassment associated with self-
injection, leading to increased adherence.27,28 These devices 
are also equipped with smaller, less intimidating needles 
that have a thinner gauge than conventional needles and may 
help dispel needle anxiety.54 According to a review about 
confidence and convenience in insulin delivery systems,27 
administering insulin with prefilled pen devices compared 
with traditional vials and syringes allows for improved 
adherence, fewer hypoglycemic events, reduced emergency 
department and physician visits, better quality of life, more 
accurate dosing, and lower annual treatment costs, thereby 
reducing many of the barriers associated with insulin use.
Nurses have reported a high level of patient satisfaction 
with pens. In an 11-month satisfaction survey, the majority 
(69%) of nurses found pens to be an improvement in insulin 
administration over the conventional method based on con-
venience, simplicity and ease of use, and time to prepare and 
administer the insulin dose. Approximately 44% of nurses 
also reported that it took less than 15 minutes to instruct 
patients on the use of pens, while 28% of nurses reported 
needing 15 minutes or less to instruct patients on the use of 
conventional vials and syringes.55
Implementing a patient-driven 
insulin titration algorithm
Once insulin is initiated, a simple, patient-driven insulin 
titration algorithm can be taught that empowers patients to 
take active control of their own diabetes management. After 
careful assessment of patient comfort level as well as ability to 
comprehend and demonstrate the information back correctly, 
patients are given a printed titration tool in which they can 
log bedtime and fasting glucose levels and make small dose 
titrations accordingly. This practice can increase the rate at 
which glucose control is improved as well as actively involve 
patients in their own insulin regimens. Examples of very 
effective patient-directed insulin titration algorithms can be 
found in the literature.56–61 In a study, patients simply tested 
their FPG and adjusted their basal insulin doses accordingly. 
For an FPG < 80 mg/dL (4.44 mmol/L), insulin was titrated 
down 3 units; if FPG was between 80 mg/dL and 110 mg/dL 
(4.44–6.11 mmol/L), the units remained unchanged; if the 
FPG was > 110 mg/dL (6.11 mmol/dL), insulin was adjusted 
up 3 units. The glycemic control achieved in the patient-
driven algorithm was equivalent to the physician-titrated 
insulin therapy.57,58
Nurses’ unique role  
in type 2 diabetes education  
and management
Clinical nurse specialists (CNSs), specialized in diabetes and 
trained to understand the behavioral aspects of living with Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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chronic illness, are especially well positioned to provide the 
patient education and coaching necessary to promote diabetes 
self-management.34,62
Motivational interviewing
Motivational interviewing is a patient-centered, passive 
  counseling style that can be used to encourage patients to 
resolve their own health-related concerns.63–65 It is an ideal 
approach for identifying reasons why patients are hesitant 
to initiate insulin. Nurses pose questions that are directive, 
designed to elicit the patients’ perceptions about the advan-
tages and disadvantages of insulin therapy, or what motivates 
patients to change certain behaviors. After listening carefully 
to individual responses, the technique involves repeating 
back what the patient said without trying to persuade; instead 
offering acceptance and reinforcement, emphasizing freedom 
of choice and self-direction.63 Structured in this way, the 
nurse is better able to determine a patient’s ability or readi-
ness for change from the discussion.
Rollnick and Miller wrote, “Motivational interviewing 
is not a technique for tricking people into doing what they 
do not want to do. Rather, it is a skillful clinical style for 
eliciting from patients their own good motivations for making 
behavioral changes in the interest of their health. It involves 
guiding more than directing, dancing rather than wrestling, 
listening at least as much as telling. The overall ‘spirit’ has 
been described as collaborative, evocative, and honoring of 
patient autonomy”.66
exploring patients’ barriers to insulin  
use and debunking insulin myths
Nurses can use motivational interviewing as part of the 
rapport-building process to explore the patient’s beliefs about 
insulin therapy and then gently begin to reposition insulin in 
a positive light. Patient barriers typically fall under a number 
of definable categories: denial of the need for insulin; mis-
conceptions about insulin; fear of injections, weight gain, and 
hypoglycemia; and complexities of insulin use. By following 
a systematic approach, patient obstacles can be identified, 
clarified, and overcome. Some common scenarios relating to 
barriers and strategies to address and overcome them are:
•  Ask patients if they understand that most patients with 
type 2 diabetes eventually require insulin, and then rein-
force the idea that insulin, when initiated promptly, can 
help delay further progression of the disease.
•  Convey that initiation of insulin is a well-established 
treatment strategy. The need for insulin does not reflect 
a failure on the patient’s part but a natural progression of 
the disease. This should help correct the misconception 
that the diabetes must be very severe if they need insulin 
and should help clear the air about denial or fear.
•  Provide information about national guidelines and explain 
that the guidelines are based on landmark studies and 
years of research. Patients will appreciate learning about 
these studies from a nurse and will likely feel more con-
fident and empowered about their disease (Table 1).
•  Identify and dispel any misconceptions about insulin 
therapy causing complications such as renal failure or 
blindness. Explain that these complications may actually 
be prevented if insulin is initiated earlier.
•  Listen to the patient’s specific concerns about weight 
gain and hypoglycemia with insulin therapy. In this case, 
the nurse’s knowledge of insulin analogs becomes an 
important part of patient education. Use the opportunity 
to introduce the patient to new technologies, explaining 
that the insulin analogs were specifically designed to 
mimic normal physiology and that they pose a lower risk 
of these unwanted effects, while providing an effective 
means of controlling hyperglycemia.
•  Teach patients about the symptoms of hypoglycemia and 
how to recognize and self-treat (Table 5).4,44,67,68 Patients’ 
concerns about hypoglycemia should also prompt a refocus 
of the discussion on nutrition. Explain to patients that they 
may feel less hungry as blood glucose improves.
•  Instruct patients with needle anxiety about new technolo-
gies, including pen devices and fine-coated needles, to 
make them more comfortable.26,69,70 For patients who still 
express injection anxiety, have them self-administer the 
first injection in your presence. If the timing is not appropri-
ate while in the clinic/office for an insulin dose, encourage 
injection of 5 “units” of saline. Most often, the patient’s 
response is “That’s it? I didn’t even feel it!” Anxiety about 
self-injection at home will be significantly reduced.27,28
•  Discuss the differences in needle gauges for patients 
who express concern about injection pain and show 
them the subcutaneous needle size. Demonstrate how an 
insulin pen device works compared with the traditional 
vial and syringe to emphasize its convenience, small 
needle size, and ease of use.69,70 Do the same with blood 
  glucose-monitoring devices.
•  Address concerns about the complexities of an insulin 
regimen by discussing premixed insulins or teach a simple 
patient-directed algorithm (refer to the earlier section 
on patient-driven insulin titration algorithms). Insulin 
pen devices also greatly simplify insulin   administration. 
Talk about the flexibility around mealtime and that Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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the rapid-  acting insulin analogs make it possible to 
  “inject-and-eat”.
•  Reinforce the patient’s role as an active decision maker 
in his/her own treatment, while offering information, 
direction, and support.14,34
insulin therapy evaluation clinics:  
a new paradigm for diabetes  
education and care by the cNs
Educational interventions organized and executed by nurses 
and centered on patient self-management are effective.71 
Nurses and physicians agree that nurses should play a larger 
role in managing diabetes.2 The CNS, with advanced practice 
skills in adult diabetes education, is ideally suited to take this 
on. CNSs are not often called on to see patients individually 
for insulin therapy evaluation; however it is an appropriate 
use of the skills of this level of nurse. Office staff nurses are 
less well suited for this role, as their focus is on acute care 
or individual physician support. The DAWN study suggested 
that, compared with primary care providers (PCPs), nurses 
tended to provide better education, spent more time with 
patients, were better listeners, and knew their patients better.34 
By taking the role of a diabetes educator as well as a care 
provider, an advanced practice nurse such as the CNS will 
improve patient–provider communication.19 Given adequate 
training and time with patients, advanced practice nurses will 
be able to play an increasingly important role in initiation and 
management of insulin therapy.34 As an example of the CNS 
involvement in diabetes management, patients are beginning 
to be referred by physicians to insulin therapy evaluation 
(ITE) or “insulin start” clinics run by CNSs. Such clinics 
fulfill a variety of patient needs; most common reasons for 
patient referrals by PCPs are listed in Table 6.
At the University of California Davis Health System 
(UCDHS), ITE clinics are conducted at several of the primary 
care network clinics. CNSs work with patient referrals from 
PCPs and see patients in 45-minute increments. Whereas 
the PCP referral sometimes indicates a specific regimen to 
initiate, more often, the CNS is asked to assess the patient 
and make recommendations for initiating insulin therapy. It 
is not uncommon to see patients on basal-bolus insulin who 
are still not optimally controlled, as evidenced by their HbA1C. 
These patients will receive counseling on carbohydrate-to-
insulin ratios, nutritional challenges, or how to adjust insulin 
bolus doses, based on blood glucose levels using correction 
factors. The use of insulin-delivery devices and blood glucose 
monitors are reviewed for all patients because problems with 
patient techniques, calculations, and injection practices are 
frequently encountered. Following each patient session, 
nursing notes are entered into the electronic medical record 
Table 6 reasons for patient referral to insulin therapy evaluation 
clinics
•   initiation of insulin for patients who are poorly controlled 
on OAD therapies 
•   insulin dose adjustments for patients who are not achieving HbA1c 
goals with basal-bolus therapy
• instruction on self-titration tools for basal insulin 
•   instruction on carbohydrate counting and carbohydrate-to-insulin 
ratios
•   evaluation of patients’ ability to self inject (includes pen-vs-syringe 
demonstrations)
• General education about the role of insulin in diabetes management
• instruction on the use of self-monitoring blood glucose monitors
• Hypoglycemia prevention and management
Table 5 symptoms and management of hypoglycemia
Hypoglycemia symptoms can vary considerably from patient to patient.44
Common symptoms
• Pallor
• sweating
• increased heart rate
• Feelings of shakiness
• Blurred vision
• Tingling sensation
• Difficulty concentrating
• Feeling weak
• Tiredness or clumsiness
• Feeling warm or cold
• Feeling hungry
•   changes in mood (manifesting as giddiness, anger or irritability, anxiety 
or frustration, or tearfulness)
• seizures or loss of consciousness (if the hypoglycemia is very severe)44
Management
Mild-to-moderate
•   Fast-acting carbohydrates (glucose tablets, fruit juices, drinks high in 
sugar content, or glucose gels).
•   Five grams of carbohydrate raises plasma glucose by ∼15 mg/dL 
(0.83 mmol/L). A typical hypoglycemic episode is treated by ingesting 
15 g of carbohydrate.4,67,68
•   if, after 15 minutes, plasma glucose remains ,70 mg/dL (3.89 mmol/L), 
another carbohydrate-rich snack should be ingested (the 15/15 rule). 
Glucose gels are absorbed by the buccal mucosa and can be 
administered by an attendant in the event the patient is not alert.  
This may be followed by juice or food once the patient is more alert.
severe
•   very severe hypoglycemia might require intravenous administration of 
glucose by trained medical personnel.
•   in cases of severe or frequent hypoglycemia or hypoglycemic 
unawareness, it is prudent to instruct the patient and significant other(s) 
in the use of glucagon, an injectable treatment for hypoglycemia in the 
unconscious patient.Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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and the PCP cosigns the chart and any insulin or supply 
orders. Currently, UCDHS is considering a shared appoint-
ment model in which multiple patients with insulin referrals 
are seen as a group. This idea stems from the Chronic Care 
Model (Table 7)72 initiative and is expected to be a cost-
effective approach.
On a smaller scale, the ITE concept can be adapted to 
an office setting. Development of an office-based nurse 
insulin initiation team would provide patients with more 
one-on-one nurse instruction and coaching. Diabetes edu-
cation protocols can be developed to guide nurses through 
all the steps necessary to educate and empower patients 
to participate in self-management. The office-based nurse 
could function in a task-focused manner, providing sup-
port for the physician or the CNS in a supervised office 
setting.
Develop and participate in follow-up 
treatment plans
In addition to managing immediate needs for glucose control 
(HbA1C, FPG, and PPG), nurse-run education and follow-up 
care is necessary to help patients maintain control of their 
diabetes over the long term. Actionable items include the 
following:2,14,19,34
•  Encourage patients to maintain recommended levels 
of blood glucose, blood pressure, microalbumin, and 
cholesterol through diligent adherence to therapy.
•  Promote lifestyle changes, such as meal planning and 
mild-to-moderate exercise.
•  Establish a schedule for timely routine screenings for 
diabetes-related complications.
•  Advocate patient participation in weekly diabetes self-
management classes at a local ADA-recognized diabetes 
program.
•  Empower patients with all of the information, tools, and 
training necessary to successfully manage their diabetes 
at home.
•  Reinforce the importance of the patient as the key   decision 
maker in his/her own care but emphasize that they can 
always rely on the guidance of the healthcare team.
•  Acknowledge that bumps in the road are to be expected, 
the best lessons learned are those that patients figure out 
on their own, and self-management of chronic conditions 
requires ongoing behavioral monitoring.
•  Stress that the goal of the entire healthcare team is for the 
patient to achieve overall targets and not perfection.
Conclusions
The most valuable role of the nurse as a diabetes case manager 
is to ensure treatment effectiveness and patient satisfaction. The 
care of patients with type 2 diabetes must be tailored toward 
individual needs, beginning with education and adoption of 
an optimized treatment regimen. Guidelines from national 
organizations, the components of patients’ daily routines, and 
individual responses to therapy are among the many factors to 
consider when setting treatment goals. For patients being initi-
ated on insulin, it is critical to understand and overcome any bar-
riers that could impair treatment success. The insulin analogs, 
premixed insulin formulations, and pen-type delivery systems 
have improved the safety, efficacy, and satisfaction for patients 
with type 2 diabetes and have all but eliminated most of the 
common barriers to insulin therapy, including hypoglycemia, 
weight gain, and inconvenience. Nurses should leverage these 
medical advancements and empower patients to self-manage 
their diabetes so they may improve the quality of their daily life 
as well as avoid potential complications later in life.
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Table 7 self-management and the chronic care model72
Nearly half of all people with chronic illness have multiple conditions. 
Insurers have an interest in correcting specific issues in chronic disease 
management, including:
•   Practitioners who, because of high caseload, are too rushed 
to consult or follow established practice guidelines 
• Lack of care coordination 
• Lack of active follow-up to ensure the best outcomes 
• Patients inadequately trained to manage their illnesses 
Notes: To overcome these issues, the improving chronic illness care organization 
created the chronic care Model, which summarizes basic elements for improving 
healthcare. The model draws on best practices and research findings and provides 
a foundation for collaborative programs, tools, and research aimed at improving 
care for the chronically ill (see http://www.improvingchroniccare.org for additional 
information and resources).72Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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